PGEN
$3.54
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through tw...
Recent News
Assessing Precigen (PGEN) Valuation After Recent Share Price Weakness And Conflicting Fair Value Estimates
Key context for Precigen’s recent share performance Precigen (PGEN) has drawn attention after a mixed stretch in its share performance, with a 2.6% decline over the past day, a 3.7% slide over the past week, and a 25% drop over the past month. See our latest analysis for Precigen. While the 1 month share price return of negative 25% suggests fading short term momentum, the 1 year total shareholder return of 92.13% and 3 year total shareholder return above 200% point to a much stronger longer...
Precision BioSciences (DTIL) Surpasses Q4 Earnings and Revenue Estimates
Precision BioSciences (DTIL) delivered earnings and revenue surprises of +271.43% and +178.08%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Beats Revenue Estimates
Foghorn Therapeutics (FHTX) delivered earnings and revenue surprises of -19.72% and +14.87%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
CorMedix (CRMD) Lags Q4 Earnings Estimates
CorMedix (CRMD) delivered earnings and revenue surprises of -29.07% and +1.03%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Precigen (PGEN) Surged Following the Early Approval of Papziemos
Patient Capital Management, a value investing firm, released its “Patient Opportunity Equity Strategy” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. In Q4 2025, Patient Opportunity Equity Strategy returned 5.99% net of fees, compared to its unmanaged benchmark, the S&P 500 Index, which returned 2.65%. Through a three-factor performance attribution model, […]